USA flag logo/image

An Official Website of the United States Government

ELECTROCHEMICAL MOLECULAR ARRAYS FOR DRUG DEVELOPMENT

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
53819
Program Year/Program:
2001 / SBIR
Agency Tracking Number:
1R43CA089911-01
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ALDERON BIOSCIENCES, INC.
120 Turner Street Beaufort, NC 28516-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2001
Title: ELECTROCHEMICAL MOLECULAR ARRAYS FOR DRUG DEVELOPMENT
Agency: HHS
Contract: N/A
Award Amount: $99,277.00
 

Abstract:

DESCRIPTION (applicant's abstract): Some 45 percent of all approved cancer products. Plants and microorganisms can be extremely useful in the production these medicines or precursors for these medicines. Collectively, photosynthetic plants and microorganisms have a broad array of biosynthetic capabilities for the production of drugs. The discovery /manipulation of gene networks in these organisms could lead to development of new medicines and to significant human health benefits. Consequently, we propose the initial stage of a multi-phase SBIR project aimed at developing and producing a line of inexpensive,high-sample-throughput, multigene assay systems ("Plant Chips") for use in testing plants and non-medical microbes and algae for their capacities to produce medicines. The Phase I proof-of-concept project is designed to demonstrate the feasibility of using the AndCare platform to detect metabolic pathways or key steps in pathways by gene-expression analysis. For Phase I, we propose to develop a prototype "algal chip" and to demonstrate its effectiveness in detecting patterns of gene expression in selected strains of marine microalgae. The chip-based assays will be designed to detect and characterize metabolic pathways that may lead to the production of drugs or drug precursors. Phase I success will set the stage for follow-on Phase II optimization and demonstration. PROPOSED COMMERCIAL APPLICATIONS: Efforts over the past 30 years have documented that species inhabiting the marine environment particularly have many unusual chemical substances, some of which will be useful in the development of pharmaceuticals. Success in carrying out the work proposed here will lead to almost unlimited potential commercial application in the drug discovery and development marketplace, addressing important needs in treating cancer and other human diseases and conditions.

Principal Investigator:

Robert W. Henkens

Business Contact:


9195448220
JODALY@ANDCARE.COM
Small Business Information at Submission:

ANDCARE
2810 MERIDIAN PKY, STE 152 DURHAM, NC 27713

EIN/Tax ID: 561458171
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No